公开(公告)号：US20130055628A1

公开(公告)日：2013-03-07

申请号：US13655450

申请日：2012-10-19

申请人： Ronald C. STITES ,  David ALDOUS

发明人： Ronald C. STITES ,  David ALDOUS

IPC分类号： C10L1/185 ,  C10L1/182

CPC分类号： C10L1/04 ,  C10L3/00

摘要： The present invention provides useful fuel compositions which may be produced substantially from renewable resources, such as biomass, to provide green fuel compositions, methods, and systems. In some embodiments, fuel compositions include dimethyl ether and one or more C2 or larger alcohol, such as ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, isobutanol, or tent-butanol. In some embodiments, fuel compositions include dimethyl ether and one or more C2 or larger hydrocarbons, such as propane, propylene, propyne, and propadiene, n-butane, isobutane, isobutylene, 1-butene, 2-butene, or 1,3-butadiene. Methods of making these novel DME-based fuel compositions, particularly from biomass-derived syngas, are described. Various applications and methods of using the fuel compositions, such as portable cylinder fuels for camping, are disclosed. Additionally, principles of burner design for these fuel compositions are disclosed herein.

摘要翻译： 本发明提供有用的燃料组合物，其可以基本上由可再生资源（例如生物质）生产，以提供绿色燃料组合物，方法和系统。 在一些实施方案中，燃料组合物包括二甲醚和一种或多种C2或更大的醇，例如乙醇，1-丙醇，2-丙醇，1-丁醇，2-丁醇，异丁醇或帐丁醇。 在一些实施方案中，燃料组合物包括二甲醚和一种或多种C 2或更大的烃，例如丙烷，丙烯，丙炔和丙二烯，正丁烷，异丁烷，异丁烯，1-丁烯，2-丁烯或1,3-丁二烯， 丁二烯。 描述了制备这些新型的基于DME的燃料组合物，特别是来自生物质衍生的合成气的方法。 公开了使用燃料组合物的各种应用和方法，例如用于露营的便携式气缸燃料。 此外，这里公开了这些燃料组合物的燃烧器设计原理。

公开(公告)号：US20120047796A1

公开(公告)日：2012-03-01

申请号：US13291107

申请日：2011-11-08

申请人： Ronald C. STITES ,  David ALDOUS

发明人： Ronald C. STITES ,  David ALDOUS

IPC分类号： C10L1/185

CPC分类号： C10L1/04 ,  C10L3/00

摘要： The present invention provides useful fuel compositions which may be produced substantially from renewable resources, such as biomass, to provide green fuel compositions, methods, and systems. In some embodiments, fuel compositions include dimethyl ether and one or more C2 or larger alcohol, such as ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, isobutanol, or tert-butanol. In some embodiments, fuel compositions include dimethyl ether and one or more C2 or larger hydrocarbons, such as propane, propylene, propyne, and propadiene, n-butane, isobutane, isobutylene, 1-butene, 2-butene, or 1,3-butadiene. Methods of making these novel DME-based fuel compositions, particularly from biomass-derived syngas, are described. Various applications and methods of using the fuel compositions, such as portable cylinder fuels for camping, are disclosed. Additionally, principles of burner design for these fuel compositions are disclosed herein.

摘要翻译： 本发明提供有用的燃料组合物，其可以基本上由可再生资源（例如生物质）生产，以提供绿色燃料组合物，方法和系统。 在一些实施方案中，燃料组合物包括二甲醚和一种或多种C2或更大的醇，例如乙醇，1-丙醇，2-丙醇，1-丁醇，2-丁醇，异丁醇或叔丁醇。 在一些实施方案中，燃料组合物包括二甲醚和一种或多种C 2或更大的烃，例如丙烷，丙烯，丙炔和丙二烯，正丁烷，异丁烷，异丁烯，1-丁烯，2-丁烯或1,3-丁二烯， 丁二烯。 描述了制备这些新型的基于DME的燃料组合物，特别是来自生物质衍生的合成气的方法。 公开了使用燃料组合物的各种应用和方法，例如用于野营的便携式气缸燃料。 此外，这里公开了这些燃料组合物的燃烧器设计原理。

公开(公告)号：US20120016058A1

公开(公告)日：2012-01-19

申请号：US12837304

申请日：2010-07-15

申请人： Stewart James WARRENDER ,  Hai Hui LIN ,  Parfait Jean Marie LIKIBI ,  Rajasekar PITCHIMANI ,  Devidas Balu RASKAR ,  David ALDOUS

发明人： Stewart James WARRENDER ,  Hai Hui LIN ,  Parfait Jean Marie LIKIBI ,  Rajasekar PITCHIMANI ,  Devidas Balu RASKAR ,  David ALDOUS

IPC分类号： C09D1/00 ,  B05D7/24 ,  C23C14/10 ,  C23C14/06 ,  C04B14/30 ,  C23C14/34

CPC分类号： C09C1/00 ,  C01G45/006 ,  C01P2002/52 ,  C01P2002/54 ,  C01P2004/61 ,  C01P2006/62 ,  C01P2006/63 ,  C01P2006/64 ,  C03C3/321 ,  C09C1/0021 ,  C09C2200/1004 ,  C09C2210/10 ,  Y10T428/252 ,  Y10T428/256 ,  Y10T428/2991 ,  Y10T428/2993 ,  Y10T428/2996

摘要： Manganese vanadium tantalum oxide that can be represented by the formula MnxVyTazOw, where 1≦x≦3, 0.001≦y≦3, 0.001≦z≦2, and w=7, and alternately, x=1.25≦x≦2.45, 0.1≦y≦2.39, 0.2≦z≦1.9, and w=7, methods of producing MnxVyTazOw, a pigment coated with MnxVyTazOw and a chalcogenide glass layer, and a method of producing the coated pigment are described. The disclosed manganese vanadium tantalum oxide has superior near-infrared reflective properties. The disclosed methods of producing the manganese vanadium tantalum oxide provide products with superior phase purity, appearance and performance and take health and safety into consideration. The construction of the disclosed coated pigment combines the reflective properties of the substrate with the near-infrared reflective properties of MnxVyTazOw, while the chalcogenide glass layer provides aesthetic appeal. The disclosed method of producing the coated pigment involves physical vapor deposition of MnxVyTazOw, and the chalcogenide glass layer.

公开(公告)号：US20070135386A1

公开(公告)日：2007-06-14

申请号：US11625369

申请日：2007-01-22

申请人： Michael Graupe ,  James Palmer ,  David Aldous ,  Sukanthini Thurairatnam

发明人： Michael Graupe ,  James Palmer ,  David Aldous ,  Sukanthini Thurairatnam

IPC分类号： A61K31/675 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/4415 ,  A61K31/381 ,  A61K31/4035

CPC分类号： C07D295/215 ,  A61K38/00 ,  C07C317/48 ,  C07C317/50 ,  C07D205/085 ,  C07D207/24 ,  C07D207/48 ,  C07D223/12 ,  C07D307/32 ,  C07K5/0606 ,  C07K5/06078 ,  Y02A50/411 ,  Y02A50/423

摘要： The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

摘要翻译： 本发明涉及新型组织蛋白酶S抑制剂，其药学上可接受的盐和N-氧化物，它们作为治疗剂的用途及其制备方法。

公开(公告)号：US20060089357A1

公开(公告)日：2006-04-27

申请号：US11296782

申请日：2005-12-07

申请人： Michael Graupe ,  James Palmer ,  John Patterson ,  Stephen Pickett ,  David Aldous ,  Sukanthini Thurairatnam ,  Andreas Timm ,  Frank Halley ,  Justine Lai ,  John Link ,  Jiayao Li

发明人： Michael Graupe ,  James Palmer ,  John Patterson ,  Stephen Pickett ,  David Aldous ,  Sukanthini Thurairatnam ,  Andreas Timm ,  Frank Halley ,  Justine Lai ,  John Link ,  Jiayao Li

IPC分类号： A61K31/537 ,  C07D265/30

CPC分类号： C07D213/40 ,  A61K31/4245 ,  A61K31/5375 ,  A61K31/5377 ,  C07C317/44 ,  C07C323/60 ,  C07D205/08 ,  C07D207/24 ,  C07D213/75 ,  C07D223/12 ,  C07D263/32 ,  C07D263/56 ,  C07D271/06 ,  C07D271/10 ,  C07D277/26 ,  C07D277/64 ,  C07D285/08 ,  C07D295/185 ,  C07D413/04 ,  C07D413/12

摘要： The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

公开(公告)号：US20050038069A1

公开(公告)日：2005-02-17

申请号：US10933077

申请日：2004-09-01

申请人： Paul Cox ,  Shelley Bower ,  David Aldous ,  Peter Astles ,  Daniel McGarry ,  Christopher Hulme ,  John Regan ,  Fu-Chih Huang ,  Stevan Djuric ,  Kevin Moriarty ,  Rose Mathew ,  Gregory Poli

发明人： Paul Cox ,  Shelley Bower ,  David Aldous ,  Peter Astles ,  Daniel McGarry ,  Christopher Hulme ,  John Regan ,  Fu-Chih Huang ,  Stevan Djuric ,  Kevin Moriarty ,  Rose Mathew ,  Gregory Poli

IPC分类号： C07D235/08 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/422 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/5355 ,  A61K31/5375 ,  A61K31/5377 ,  A61P9/00 ,  A61P11/00 ,  A61P17/00 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00 ,  C07D209/08 ,  C07D209/12 ,  C07D209/42 ,  C07D235/12 ,  C07D235/24 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D217/12

CPC分类号： C07D235/24 ,  C07D209/12 ,  C07D209/42 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

摘要： This invention is directed to physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; R1 represents hydrogen or a straight- or branched-chain alkyl group of 1 to about 4 carbon atoms, optionally substituted by hydroxy or one or more halogen atoms, or when Z1 represents a direct bond R1 may also represent a lower alkenyl or lower alkynyl group, or a formyl group; R2 represents hydrogen, alkenyl, alkoxy, alkyl, alkylsulphinyl, alkylsulphonyl, alkylthio, aryl, arylalkyloxy, arylalkylsulphinyl, arylalkylsulphonyl, arylalkylthio, aryloxy, arylsulphinyl, arylsulphonyl, arylthio, cyano, cycloalkenyl, cycloalkenyloxy, cycloalkyl, cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy, hydroxy, —SO2NR4R5, —NR4SO2R5, —NR4R5, —C(═O)R5, —C(═O)C(═O)R5, —C(═O)NR4R5, —C(═O)OR5, —O(C═O)NR4R5, or —NR4C(═O)R5; R3 represents —C(=Z)—N(R7)R6, —C(=Z)—CHR12R6, —C(=Z)—R6, —CR8═C(R9)(CH2)p—R6, —C(R10)═C(R11)R12, —C(R13)(R10)C(R11)(R14)R12, —C(R8)(R15)CH(R9)(CH2)p—R6, —R6, —N(R16)C(=Z)R6, —C(R17)═N—OC(=0)R18, —C(═O)—N(R19)OR20, —C≡C—R6, —CH2—C(=Z)—R6, —C(=Z)—C(=Z)R6, —CH2—NHR6, —CH2-ZR6, —CH2—SOR6, —CH2—SO2R6, —CF2—OR6, —NH—CH2R6, -Z-CH2R6, —SO—CH2R6, —SO2—CH2R6, —O—CF2R6, —O—C(=Z)R6, —N═N—R6, —NH—SO2R6, —SO2—NR21R22, —CZ-CZ-NHR6, —NH—CO—OR6, —O—CO—NHR6, —NH—CO—NHR6, —R23, —CX1═CX2R6, —C(═NOR24), —(CH2)qR6, —CH2—CO—NH(CH2)qR6, —CH2—NH—CO(CH2)qR6, —CH2—CO—CH2R6, —C(═NR25)—NH(CH2)qR6, —C(X3)═N—(CH2)qR6 or —CH(X4)—CH2R6; A1 represents a direct bond, or a straight or branched C1-6 alkylene chain optionally substituted by hydroxyl, alkoxy, oxo, cycloalkyl, aryl or heteroaryl, or A1 represents a straight or branched C2-6alkenylene or C2-6alkynylene chain; Z1 represents a direct bond, an oxygen or sulphur atom or NH; n and m each represent zero or 1, provided that n is 1 when m is zero and n is zero when m is 1; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (I) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.

摘要翻译： 本发明涉及式（I）的生理活性化合物，其中代表双环体系，约10至约13个环成员，其中该环是氮杂环，并且该环代表氮杂杂芳基环，或任选地被卤素取代 苯环; R 1表示氢或1至约4个碳原子的直链或支链烷基，任选被羟基或一个或多个卤素原子取代，或当Z 1表示直接键R 1时 也代表低级烯基或低级炔基或甲酰基; R 2表示氢，烯基，烷氧基，烷基，烷基亚磺酰基，烷基磺酰基，烷硫基，芳基，芳基烷氧基，芳基烷基亚磺酰基，芳基烷基磺酰基，芳基烷硫基，芳氧基，芳基亚磺酰基，芳基磺酰基，芳硫基，氰基，环烯基，环烯氧基，环烷基，环烷氧基，杂芳基， ，杂芳氧基，羟基，-SO 2 NR 4 R 5，-NR 4 SO 2 R 5，-NR 4 R 5，-C（= O）R 5，-C（= O）C（= O）R 5，-C（= O）NR 4 R 5，-C（= O）OR 5，-O（C = O）NR 4 R 5或-NR 4 C（= O）R 5; R 3表示-C（= Z）-N（R 7）R 6，-C（= Z）-CHR 12 R 6，-C（= Z）-R 6 ，-CR 8 = C（R 9）（CH 2）p R 6，-C（R 10）= C（R 11）R 12，-C（R 13） （R 10）C（R 11）（R 14）R 12，-C（R 8）（R 15）CH（R 9）（CH 2） pR 6，-R 6，-N（R 16）C（= Z）R 6，-C（R 17）= N-OC（= O）R 18， -C（= O）-N（R <19）

公开(公告)号：US20070049594A1

公开(公告)日：2007-03-01

申请号：US11295890

申请日：2005-12-07

申请人： Michael Graupe ,  John Patterson ,  David Aldous ,  Sukanthini Thurairatnam ,  Andreas Timm ,  John Link ,  Jiayao Li ,  Stephen Pickett ,  Frank Halley ,  Justine Lai

发明人： Michael Graupe ,  John Patterson ,  David Aldous ,  Sukanthini Thurairatnam ,  Andreas Timm ,  John Link ,  Jiayao Li ,  Stephen Pickett ,  Frank Halley ,  Justine Lai

IPC分类号： A61K31/501 ,  A61K31/50 ,  A61K31/4965 ,  A61K31/497 ,  C07D417/02 ,  C07D413/02

CPC分类号： C07D207/273 ,  A61K31/5375 ,  A61K31/5377 ,  C07C317/44 ,  C07C323/60 ,  C07D205/08 ,  C07D207/24 ,  C07D213/40 ,  C07D223/10 ,  C07D223/12 ,  C07D263/32 ,  C07D263/56 ,  C07D271/06 ,  C07D271/10 ,  C07D277/26 ,  C07D277/64 ,  C07D285/08 ,  C07D295/185 ,  C07D413/04 ,  C07D413/12 ,  Y02A50/411

摘要： The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

摘要翻译： 本发明涉及新的选择性组织蛋白酶S抑制剂，其药学上可接受的盐和N-氧化物，它们作为治疗剂的用途及其制备方法。

公开(公告)号：US08187705B2

公开(公告)日：2012-05-29

申请号：US12837304

申请日：2010-07-15

申请人： Stewart Warrender ,  Hai Hui Lin ,  Parfait Jean Marie Likibi ,  Rajasekar Pitchimani ,  Devidas Balu Raskar ,  David Aldous

发明人： Stewart Warrender ,  Hai Hui Lin ,  Parfait Jean Marie Likibi ,  Rajasekar Pitchimani ,  Devidas Balu Raskar ,  David Aldous

IPC分类号： B32B27/20 ,  B32B1/00 ,  B32B33/00 ,  B05D1/36 ,  B05D5/00 ,  C01G31/02 ,  C01G35/00 ,  C01G45/00 ,  F21V9/04

CPC分类号： C09C1/00 ,  C01G45/006 ,  C01P2002/52 ,  C01P2002/54 ,  C01P2004/61 ,  C01P2006/62 ,  C01P2006/63 ,  C01P2006/64 ,  C03C3/321 ,  C09C1/0021 ,  C09C2200/1004 ,  C09C2210/10 ,  Y10T428/252 ,  Y10T428/256 ,  Y10T428/2991 ,  Y10T428/2993 ,  Y10T428/2996

摘要： Manganese vanadium tantalum oxide that can be represented by the formula MnxVyTazOw, where 1≦x≦3, 0.001≦y≦3, 0.001≦z≦2, and w=7, and alternately, x=1.25≦x≦2.45, 0.1≦y≦2.39, 0.2≦z≦1.9, and w=7, methods of producing MnxVyTazOw, a pigment coated with MnxVyTazOw and a chalcogenide glass layer, and a method of producing the coated pigment are described. The disclosed manganese vanadium tantalum oxide has superior near-infrared reflective properties. The disclosed methods of producing the manganese vanadium tantalum oxide provide products with superior phase purity, appearance and performance and take health and safety into consideration. The construction of the disclosed coated pigment combines the reflective properties of the substrate with the near-infrared reflective properties of MnxVyTazOw, while the chalcogenide glass layer provides aesthetic appeal. The disclosed method of producing the coated pigment involves physical vapor deposition of MnxVyTazOw and the chalcogenide glass layer.

摘要翻译： 锰钒氧化钽，其可以由式Mn x V y TazOw表示，其中1＆nlE; x＆nlE; 3，0.001＆nlE; y＆nlE; 3，0.001＆nlE; z＆nlE; 2和w = 7，或者，x = 1.25＆nlE; x＆ ，0.1＆nlE; y＆nlE; 2.39,0.2＆nlE; z＆nlE; 1.9和w = 7，描述了生产MnxVyTazOw的方法，涂覆有Mn x V y TazOw和硫族化物玻璃层的颜料以及制备涂层颜料的方法。 所公开的锰钒氧化钽具有优异的近红外反射性能。 所公开的锰钒钽氧化物的制造方法提供具有优异的相纯度，外观和性能的产品，并考虑健康和安全性。 所公开的涂层颜料的结构将基材的反射性能与Mn x V y TazOw的近红外反射性质结合，而硫族化物玻璃层提供了美学吸引力。 所公开的生产涂层颜料的方法包括物理气相沉积Mn x V y TazOw和硫族化物玻璃层。

公开(公告)号：US20070203138A1

公开(公告)日：2007-08-30

申请号：US11740414

申请日：2007-04-26

申请人： Jiayo Li ,  David Aldous ,  Sukanthini Thurairatnam

发明人： Jiayo Li ,  David Aldous ,  Sukanthini Thurairatnam

IPC分类号： A61K31/5377 ,  A61K31/4439 ,  A61K31/4245

CPC分类号： C07D271/10 ,  A61K31/4245 ,  A61K31/4439 ,  A61K31/5377 ,  C07D271/06 ,  C07D401/04 ,  C07D409/04 ,  Y02A50/411

摘要： The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

摘要翻译： 本发明涉及新的选择性组织蛋白酶S抑制剂，其药学上可接受的盐和N-氧化物，它们作为治疗剂的用途及其制备方法。

公开(公告)号：US20060189657A1

公开(公告)日：2006-08-24

申请号：US11409601

申请日：2006-04-24

申请人： Sukanthini Thurairatnam ,  David Aldous ,  Vincent Leroy ,  Andreas Timm

发明人： Sukanthini Thurairatnam ,  David Aldous ,  Vincent Leroy ,  Andreas Timm

IPC分类号： A61K31/445 ,  A61K31/4015

CPC分类号： C07D263/56 ,  A61K38/00 ,  C07D263/32 ,  C07D267/10 ,  C07D271/06 ,  C07D271/10 ,  C07D271/107 ,  C07D295/195 ,  C07D295/215 ,  C07D413/04 ,  C07D413/12 ,  C07K5/06191

摘要： Novel inhibitors of cathepsin S, K, B, and L, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

摘要翻译： 组织蛋白酶S，K，B和L的新型抑制剂，其药学上可接受的盐和N-氧化物，它们作为治疗剂的用途及其制备方法。